AI assistant
Morepen Laboratories Ltd. — Capital/Financing Update 2025
Apr 11, 2025
59389_rns_2025-04-11_596e9332-91f7-48b8-9e5c-33afb621985e.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [92 x 841] intentionally omitted <==
==> picture [80 x 73] intentionally omitted <==
==> picture [159 x 37] intentionally omitted <==
Date: 11/04/2025
To,
National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400 051 Symbol: MOREPENLAB
BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400 001 Scrip Code: 500288
Subject: Press Release – ‘Morepen Set For Bold Expansion: To Add 1000 Medical Representatives’
Dear Sir/ Madam,
Please find enclosed press release with the title ‘ Morepen Set For Bold Expansion: To Add 1000 Medical Representatives’ .
This is for your information and dissemination on your website.
Thanking you,
Yours faithfully,
For Morepen Laboratories Limited SIGN Vipul Digitally signed by Vipul Kumar Kumar Srivastava Srivastava Date: 2025.04.11 08:47:15 +05'30' Vipul Kumar Srivastava Company Secretary F-12148
Encl.: a/a.
Morepen Laboratories Limited
CIN NO. L24231 HP1984PLC006028
Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA TEL.: +91 124 4892000, E-mail: [email protected], Website: www.morepen.com
Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: [email protected]
==> picture [112 x 46] intentionally omitted <==
Morepen Set For Bold Expansion: To Add 1000 Medical Representa�ves
Gurugram, April 11, 2025 – Morepen Laboratories Ltd., one of India’s leading pharmaceu�cal companies, today announced a bold expansion plan aimed at deepening its connect with doctors, pa�ents, pharmacies, and healthcare professionals across the country. As part of this strategic ini�a�ve, the company will add more than 1,000 professionals to its salesforce over the next three years, with over 200 team members expected to join in FY26 alone.
in strengthening Morepen’s formula�ons business in the market, reinforcing its commitment to building a stronger domes�c footprint and aligning with India’s vision of affordable, accessible healthcare for all.
"This expansion represents a pivotal moment in Morepen’s journey as we sharpen our focus on the expanding domes�c finished dosage market," said Mr. Sushil Suri, Chairman and Managing Director of Morepen Laboratories . "With the leadership in our high value APIs, this significant increase in our salesforce and enhanced reach to doctors, pharmacies, and pa�ents, we are se�ng the stage for ge�ng a bigger pie in the Indian pharmaceu�cal market valued at ₹2.38 lakh crore, yielding higher gross margins and be�er returns for stakeholders in the long run.”
==> picture [452 x 255] intentionally omitted <==
Currently, Morepen’s formula�on business stands at approximately ₹ 325 crore, and the company is targe�ng a ₹1,000 crore finished dosages business within the next five years . This goal will be supported by an aggressive expansion of its medical representa�ve network and deeper market penetra�on across urban and rural India, with major growth expected from new products that the company is already producing at highly compe��ve costs.
==> picture [112 x 46] intentionally omitted <==
The Indian pharmaceu�cal market is projected to reach $130 billion in 2030, with an expected annual growth rate of 8.2%. With our strong presence and proven product por�olio, we are well-posi�oned to tap into this opportunity and further solidify our presence in the domes�c healthcare ecosystem. Coupled with robust manufacturing capabili�es, this strategy enables us to be�er serve the evolving needs of Indian healthcare while con�nuing our trajectory of double-digit growth. India is emerging as the pharmacy of the world, and we are proud to play a key role in that transforma�on.
Morepen’s expansion builds on its strong legacy as India’s number one APIs exporter for six leading products including Loratadine, Montelukast, Desloratadine, Atorvasta�n, Rosuvasta�n, and Fexofenadine. The company con�nues to reinforce investor confidence through consistent financial performance, global quality standards, and a forward-looking growth strategy.
A Vision Rooted in India’s Pharma Growth Story
India has righ�ully earned its global reputa�on as the “Pharmacy of the World.” With this expansion, Morepen is reaffirming its commitment to that legacy—ensuring that high-quality, affordable medicines are accessible to every corner of India.
Morepen’s India-centric strategy, powered by its people, execu�on strength, and deep market insights, is set to contribute meaningfully to the next chapter of India’s pharmaceu�cal success story.
About Morepen Laboratories Ltd.
Morepen Laboratories, established in 1984, is a leading player in the pharmaceu�cal and healthcare industry. With a strong presence in APIs, medical devices, and finished formula�ons, Morepen has consistently demonstrated innova�on and market leadership. The company is a global leader in expor�ng 6 key API products, including Loratadine, Montelukast, Desloratadine, Atorvasta�n, and Fexofenadine.
In the medical devices segment, Morepen has made remarkable strides in Point of Care (POC) diagnos�cs, having installed over 12.33 million glucometers and sold nearly 1.65 billion blood glucose strips, driving expansion into �er-2 and �er-3 ci�es.
For more details, visit www.morepen.com.
Media Contact:
Morepen Laboratories Ltd.
Email: [email protected]
Ni�ka Saini, Manager – Corporate Communica�on | +91 9818533004
Forward-Looking Statements:
This press release contains forward-looking statements based on current expecta�ons and assump�ons regarding an�cipated developments and other factors affec�ng the company. These statements are subject to risks and uncertain�es that could cause actual results to differ materially from those expressed in the forward-looking statements.